Commercial StrategyMainz Biomed's decentralized commercial strategy includes partnering with lab groups to reduce marketing and infrastructure expenses, and gain access to large physician networks.
Market OpportunityExisting tests with a similar format, such as Cologuard, have achieved commercial success with over $2B in annual sales, presenting an opportunity for Mainz Biomed to capture share.
Product PerformanceMainz Biomed's Next Generation Test leverages mRNA biomarkers to expand the ability to detect pre-cancerous advanced adenomas, enabling prevention of CRC.